NCT07061145
- Conditions
- Bone Marrow Diseases, CVD - Cardiovascular Disease, Cardiovascular Diseases, +23 more
- Locations
-
- Azienda USL IRCCS di Reggio Emilia Reggio Emilia, RE, Italy
Clinical trial condition
Tyrosine Kinase Inhibitor
Explore clinical trials studying Tyrosine Kinase Inhibitor. Study availability and eligibility vary by location and protocol.
15 public trials
5 recruiting studies
Tyrosine Kinase Inhibitor trial results
Recruiting
The TASTY-training Study
NCT07258589
- Conditions
- Oncological Patients, Tyrosine Kinase Inhibitor
- Locations
-
- Amsterdam UMC Amsterdam, Netherlands
- Rijnstate Ziekenhuis Arnhem, Netherlands
- Van Weel-Bethesda Ziekenhuis Dirksland, Netherlands
- Ziekenhuisvoorzieningen Gelderse Vallei Ede, Netherlands
NCT07092202
- Conditions
- Central Nervous System Neoplasms, Intrathecal Chemotherapy, Leptomeningeal Metastasis, +8 more
- Locations
-
- Wuhan Union Hospital Wuhan, Hubei, China
NCT06755684
- Conditions
- Antineoplastic Agents, Bevacizumab, Bronchial Neoplasms, +15 more
- Locations
-
- Shanghai Pulmonary Hospital Shanghai, Shanghai Municipality, China
NCT05221372
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more
- Locations
-
- Erasmus MC Rotterdam, Netherlands
Not yet recruiting
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
NCT06662877
- Conditions
- Biliary Tract Cancer, Biliary Tract Diseases, Biliary Tract Neoplasms, +7 more
- Locations
-
- The First Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China
Not yet recruiting
Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL
NCT06658925
- Conditions
- HSCT, Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Tyrosine Kinase Inhibitor
- Locations
-
Not specified
Not yet recruiting
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
NCT06538935
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
Not specified
Active, not recruiting
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
NCT06632106
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
- Locations
-
- The first hospital of China medical university Shenyang, Liaoning, China
Active, not recruiting
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166
- Conditions
- Adnexal Diseases, Angiogenesis, Anlotinib, +22 more
- Locations
-
- Huai'an First People's Hospital Huai'an, China
- Nanjing Drum Tower Hospital Nanjing, China
- Zhongda Hospital Southeast University Nanjing, China
- The First Affiliated Hospital of Soochow University Suzhou, China